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Clinical Risk Prediction Scores in Coronavirus 
Disease 2019: Beware of Low Validity and 
Clinical Utility
Abstract: Several risk stratification tools were developed to pre-
dict disease progression in coronavirus disease 2019, with no 
external validation to date. We attempted to validate three pre-
viously published risk-stratification tools in a multicenter study. 
Primary outcome was a composite outcome of development of 
severe coronavirus disease 2019 disease leading to ICU admission 
or death censored at hospital discharge or 30 days. We collected 
data from 169 patients. Patients were 73 years old (59–82 yr old), 
66 of 169 (39.1%) were female, 57 (33.7%) had one comorbidity, 
and 80 (47.3%) had two or more comorbidities. Area under the 
receiver operating characteristic curve (95% CI) for the COVID-
GRAM score was 0.636 (0.550–0.722), for the CALL score 0.500 
(0.411–0.589), and for the nomogram 0.628 (0.543–0.714).
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To the Editor:
We found that three risk tools (COVID-GRAM, CALL-TOOL, and a nomogram) developed in small, homog-enous patient populations showed poor discrimination 
in a multicenter study and are unlikely to be clinically useful in 
different settings. Re-evaluation of these tools is urgently needed 
using international datasets.
Since the outbreak of the severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) pandemic in January 2020, there has 
been a rush to develop clinical risk prediction scores, particularly 
at the first epicenter of the pandemic in China (1–3). Predicting 
risk of deterioration or severe coronavirus disease 2019 (COVID-
19)–related illness is of significant interest, both as part of guid-
ance for clinical treatment and resource allocation as well as to 
highlight the likely groups benefitting from novel disease modify-
ing therapies. The RECOVERY trial demonstrated that dexameth-
asone treatment offers mortality advantage in patients needing 
oxygen therapy or mechanical ventilation, whereas it might be 
harmful in patients who do not need supplemental oxygen (4). 
These results emphasize the need for a reliable risk prediction 
scores, which might help providers to decide about therapeutic 
approaches. Notwithstanding the urgency, we must not forget past 
lessons learnt during developing risk scores for diseases and con-
ditions encompassing a wide range of clinical risk. We have shown 
in sepsis that conflicting definitions with ill-calibrated tools lead 
to the overprovision of medical therapy, with potential for associ-
ated harm (5).
Although many of the risk prediction tools were developed in 
multicenter studies, their external clinical utility and face validity 
have not been established in independent cohorts (6). There are 
significant differences between the respective populations affected 
by SARS-CoV-2 in China compared with the United Kingdom, 
and we attempted to validate three previously published risk-strat-
ification tools in a multicenter study.
Anonymized patient data were collected as part of a service 
evaluation project by the Secondary Care Group Members of the 
Welsh Government COVID-19 response from patients admitted 
to the University Hospital of Wales, a tertiary academic center, 
and to the two district general hospitals in Aneurin Bevan UHB 
during the first 6 weeks of the pandemic in Wales, between March 
9, 2020, and April 19, 2020. Due to the anonymized nature of the 
data collection, formal written consent was waived by the institu-
tional review board.
Data were collected to enable to calculate the CALL score, the 
COVID-GRAM risk score, and a nomogram developed by Gong 
et al (1–3). Primary outcome was a composite outcome of devel-
opment of severe COVID-19 disease leading to ICU admission or 
death, in line with the definitions and outcomes used in the origi-
nal publications. The outcome was censored at hospital discharge 
or 30 days.
For statistical analysis, receiver operating characteristics (ROC) 
curves were used to establish predictive ability. We planned to 
use calibration plot to assess calibration of the prediction tools if 
area under the area under the ROC (AUROC) curve for any of 
the tools was found to be above 0.8 (good discrimination ability). 
Data are presented as n (%), median (interquartile range), or ROC 
(95% CI) as appropriate.
We collected data from 169 patients. Patients were 73 years old 
(59–82 yr old), 66 of 169 (39.1%) were female, 32 (18.9%) had no 
significant comorbidities, 57 (33.7%) had one comorbidity, and 80 
(47.3%) had two or more comorbidities. Most prevalent comorbid 
conditions were diabetes in 42 patients (24.9%), chronic obstruc-
tive pulmonary disease in 32 patients (19.0%), and ischemic heart 
disease in 26 patients (15.4%). Patients presented after 9 days 
(2–12 d) of symptom onset to the hospital. Eighty-one patients 
(47.9%) had reached the composite outcome of ICU admission or 
death, the hospital mortality was 33.7%. Neither of the three risk-
prediction tools were able to accurately predict outcome. AUROC 
(95% CI) for the COVID-GRAM score was 0.636 (0.550–0.722) 
p value equals to 0.003, for the CALL score 0.500 (0.411–0.589) 
p value equals to 0.997, and for the nomogram 0.628 (0.543–0.714) 
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p value equals to 0.005 (Fig. 1). As none of the tools exhibited 
good discrimination characteristics, we have not performed for-
mal assessment of calibration. The COVID-GRAM tool under-
performed in the medium risk category: 40% of our patients 
experienced the predicted composite outcome versus 7.3% in the 
original cohort. The CALL score underpredicted the outcome in 
the 7–9 points (medium risk) category (10–40% predicted vs 52% 
actual occurrence) and overpredicted in the 10–13 (high risk) cat-
egory (over 50% predicted vs 46% actual occurrence). The nomo-
gram overpredicted the outcome: out of the 108 patients where the 
nomogram predicted over 90% chance for the composite outcome 
to manifest, only 61 (56.5%) experienced it.
All three clinical risk prediction scores, the CALL score, 
COVID-GRAM risk score, and nomogram, had poor discrimina-
tive value for the composite outcome of ICU admission or death 
within our cohort. The COVID-GRAM risk score (derived from 
n = 2300 patients) performed better than the CALL score 
(n = 208) and narrowly better than the nomogram developed by 
Gong et al (3) (n = 372), as evidenced by the AUROC.
Our findings highlight the difficulties of predictive tool devel-
opment for a new disease with uncertain and potentially chang-
ing outcomes (7). The discriminatory performance of the three 
different models was well below the performance compared with 
their derivation or validation cohort, in line with recent findings 
of a large U.K. dataset (8). This questions if the proposed models 
could transfer over to a different setting and could offer reason-
able performance. The difference observed between the precision 
of these tools in the original publications and in our independent 
cohort in a different location could be explained by several factors. 
Some of this might be population based, as were significant differ-
ences between the patient characteristics of these three studies and 
ours. Importantly, the mean or median age was below 50 years in 
the development and validations cohorts of the original publica-
tions, whereas it was above 70 in our study in line with observed 
characteristics in the United Kingdom (9). Han Chinese patients 
in the original studies had low comorbidity burden with 70–75% 
of patients without any significant comorbidities, whereas four of 
five in our largely Caucasian cohort had one or more comorbidi-
ties, again in line with the data from the International Severe Acute 
Respiratory and Emerging Infection Consortium (ISARIC)  study 
(9). As age and comorbidities are established risk factors for disease 
progression and adverse outcome in COVID-19, it is unsurpris-
ing that the predictive scores developed in a young and relatively 
healthy population do not perform well in an older cohort with 
significant comorbidities (7, 8). It is also possible that there were 
differences in standard of care; however, our cohort was admitted 
to the hospital at the very beginning of the U.K. phase of the pan-
demic, when there were no established treatment options (10).
All three tools overestimated the morbidity and mortality, espe-
cially in those with a higher comorbidity burden. This issue highlights 
significant questions about the development of such tools that use 
small sample sizes. The original studies used regression analysis to 
derive the significant variables incorporated in their scores. Although 
the least absolute shrinkage and selection operator regression used by 
two groups is regarded as more appropriate than the Cox-regression 
used in the third study, with their low event rate, these models suffer 
a significant reduction in predictive capabilities when used in a rela-
tively small sample size. The small number of events in the three stud-
ies compared with the number of variables used makes overfitting a 
real possibility (7). This is illustrated by our finding that we observed 
underprediction in the low-risk and overprediction in the high-risk 
groups, both recognized features of an overfitting model (11).
Furthermore, predictive accuracy of all three tools was only 
assessed by ROC analysis without any other alternative method 
such as a discrimination slope (12).
Generally, when the discrimination 
of a clinical risk prediction tool is sat-
isfactory, it is necessary to investigate 
the quality of the calibration to ensure 
there is acceptable agreement between 
the observed occurrence of ICU admis-
sion and death and the risk predicted 
by the score. Liang et al 12) did not pro-
vide any data on the calibration of their 
COVID-GRAM model. The use of a 
calibration plot would have the added 
benefit of assessing the overfitting of 
the model, allowing for the fine-tuning 
of regression coefficients if indicated 
for better clinical utility (12). On the 
other hand, the nomogram developed 
by Gong et al (3) and the CALL score 
both had adequate discrimination with 
respect to their training and valida-
tion cohorts as well as calibration data, 
in the form of a calibration curve, for 
the probability of developing severe 
COVID-19 disease. Their calibration 
Figure 1. Receiver operating characteristic curves to describe predictive capabilities of the three risk 
stratification tools.
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curves showed well-fitted agreement between the nomogram and 
CALL score prediction and actual benefit according to their datasets. 
However, part of the reason for the poor discriminative value in both 
cases concerning our cohort is likely due to the small and homog-
enous training and validation cohorts used in its development.
Very recently, using the currently largest clinical dataset of 
almost 60,000 patients from the ISARIC 4C (Coronavirus Clinical 
Characteristics Consortium) group published the development 
and validation of the 4C score (8). Their model showed good dis-
crimination, excellent calibration, and resilient to imputation of 
missing values (8). They also noted that the more elaborate scores, 
such as we have investigated, could be applied to a smaller sub-
set of patients, as some physiologic variables or laboratory values 
are not routinely recorded. Although it was not an issue in our 
population, collection of diverse clinical information might not be 
feasible in the pandemic, even in a developed healthcare system, 
increasing the fragility of the prediction model.
There is a temptation to use more sophisticated tools for out-
come prediction, such as artificial intelligence–based methods or 
using electronic healthcare records when individual patient data 
are not available; however, there is a significant question about the 
clinical usefulness of such models (13, 14). It is unclear if the effort 
to improve discriminatory capability by adding new variables and 
more complicated methods or the use of just historical data to sort 
patients into broad high and low risk categories actually changes 
the answer to the clinical question and of benefit.
In the fast changing landscape of the pandemic, with emerging 
and rapidly adopted new treatment options and more sophisti-
cated phenotyping of the immune response, plus possible changes 
in the characteristics of the virus, it is unlikely that one prediction 
model will be able to answer all the questions (4, 15, 16). However, 
any new prediction models should be developed and reported in 
accordance with the guidance of best practice (7).
There are significant limitations to our study, most importantly 
the small sample size. To limit the number of patients recruited was 
a pragmatic decision, so we could rapidly assess the face validity 
of these tools. However, we have recruited all consecutive patients 
admitted to the three hospitals, reducing selection bias. Our patient 
cohort showed strong similarities to the U.K.-wide ISARIC dataset, 
and arguably, our patients who were recruited from a tertiary center, 
from a medium and small district general hospital, give appropriate 
cross-sectional view to evaluate the usefulness of these scoring tools 
(9). The relatively late presentation to hospital following the onset 
of symptoms could also be seen as a limitation, as it is possible, that 
by adhering to the national guidance of “Stay at home”, patients pre-
sented with significantly more advanced disease, than in the devel-
opment cohorts in China. Further analysis of this potential effect 
would be possible in the large international datasets.
In summary, our results show that the early tools developed in a rel-
atively small, homogenous patient population are unlikely to be clini-
cally useful in different settings. There is a continued need to develop 
reliable, easy-to-use risk stratifications tools, from commonly available 
clinical variables, according to the guiding principles for predictive 
model development. We must scrutinize new tools using international 
datasets to achieve better and more universal discrimination and cali-
bration of risk prediction tools for patients with COVID-19.
All authors contributed to the study conception and design. 
Material preparation, data collection and analysis were performed 
by Drs. Al Hassan, Cocks, Jesani, and Lewis. The first draft of 
the article was written by Drs. Al Hassan and Szakmany, and all 
authors commented on previous versions of the article. All authors 
read and approved the final article.
The authors have not disclosed any potential conflicts of 
interest. 
Haamed Al Hassan, MB BCh, Cardiff and Vale University Health 
Board, Cardiff, United Kingdom, and Department of Anaesthesia, 
Intensive Care and Pain Medicine, Division of Population Medicine, 
Cardiff University, Cardiff, United Kingdom; Eve Cocks, DN, 
Lara Jesani, MB BCh, Critical Care Directorate, Aneurin Bevan 
University Health Board, Newport, United Kingdom; Sally Lewis, 
MRCGP, Value Based Healthcare Team, Aneurin Bevan University 
Health Board, Newport, United Kingdom; Tamas Szakmany, 
MD, PhD, Department of Anaesthesia, Intensive Care and Pain 
Medicine, Division of Population Medicine, Cardiff University, 
Cardiff, United Kingdom and Critical Care Directorate, Aneurin 
Bevan University Health Board, Newport, United Kingdom; on 
behalf of the Gwent COVID-19 Group
ACKNOWLEDGMENTS
We would like to thank the Gwent Coronavirus Disease 2019 Group 
members for their support in data collection: A. Allen-Ridge, E. 
Baker, C. Bailey, T. Baumer, S. Beckett, S. Champanerkar, Y. Cheema, 
S. Cherian, E. Cocks, S. Cutler, E. Dawe, A. Dhadda, S. Dumont, N. 
Duric, S. Elgarf, T. Evans, E. Godfrey, L. Harding, D. Hepburn, A. 
E. Heron, L. Jesani, P. Jones, C. Killick, C. King, A. Kiss, J. Lavers, J. 
Lloyd-Evans, N. Mason, L. McClelland, B. Muthuswamy, J. Parry-
Jones, E. Phillips, S. Pooley, B. Radford, O. Richards, A. Rimmer, G. 
Roberts, A. Roynon-Reed, A. Sieunarine, K. Sullivan, T. Szakmany, 
C. Thomas, E. Thomas, J. Tozer, T. West, and M. Winstanley.
REFERENCES
 1. Ji D, Zhang D, Xu J, et al: Prediction for progression risk in patients 
with COVID-19 pneumonia: The CALL score. Clin Infect Dis 2020; 
71:1393–1399
 2. Liang W, Liang H, Ou L, et al; China Medical Treatment Expert Group for 
COVID-19: Development and validation of a clinical risk score to predict 
the occurrence of critical illness in hospitalized patients with COVID-19. 
JAMA Intern Med 2020; 180:1081–1089
 3. Gong J, Ou J, Qiu X, et al: A tool for early prediction of severe coronavirus 
disease 2019 (COVID-19): A multicenter study using the risk nomogram 
in Wuhan and Guangdong, China. Clin Infect Dis 2020; 71:833–840
 4. The RECOVERY Collaborative Group: Dexamethasone in hospitalized 
patients with Covid-19 — preliminary report. N Engl J Med 2020 Jul 17. 
[online ahead of print]
 5. Kopczynska M, Sharif B, Unwin H, et al: Real world patterns of antimi-
crobial use and microbiology investigations in patients with sepsis out-
side the critical care unit: Secondary analysis of three nation-wide point 
prevalence studies. J Clin Med 2019; 8:1337
 6. Wynants L, Van Calster B, Collins GS, et al: Prediction models for diag-
nosis and prognosis of covid-19: Systematic review and critical appraisal. 
BMJ 2020; 369:m1328
 7. Leisman DE, Harhay MO, Lederer DJ, et al: Development and reporting 
of prediction models: Guidance for authors from editors of respiratory, 
sleep, and critical care journals. Crit Care Med 2020; 48:623–633
 8. Knight SR, Ho A, Pius R, et al: Risk stratification of patients admitted to 
hospital with covid-19 using the ISARIC WHO clinical characterisation 
Letter to the Editor
4 www.ccejournal.org 2020 • Volume 2 • e0253
protocol: development and validation of the 4C mortality score. BMJ 
2020; 370:m3339
 9. Docherty AB, Harrison EM, Green CA, et al: Features of 20 133 UK patients 
in hospital with covid-19 using the ISARIC WHO clinical characterisation 
protocol: Prospective observational cohort study. BMJ 2020; 369:m1985
 10. Baumer T, Phillips E, Dhadda A, et al: Epidemiology of the first wave 
of COVID-19 ICU admissions in South Wales – the interplay between 
ethnicity and deprivation. Front Med 2020; 7:650
 11. Pavlou M, Ambler G, Seaman SR, et al: How to develop a more accurate 
risk prediction model when there are few events. BMJ 2015; 351:h3868
 12. Steyerberg EW, Vickers AJ, Cook NR, et al: Assessing the performance 
of prediction models: A framework for traditional and novel measures. 
Epidemiology 2010; 21:128–138
 13. Tong DL, Kempsell KE, Szakmany T, et al: Development of a bioinformat-
ics framework for identification and validation of genomic biomarkers 
and key immunopathology processes and controllers in infectious and 
non-infectious severe inflammatory response syndrome. Front Immunol 
2020; 11:380
 14. Barda N, Riesel D, Akriv A, et al: Developing a COVID-19 mortality 
risk prediction model when individual-level data are not available. Nat 
Commun 2020; 11:4439
 15. Sinha P, Calfee CS, Cherian S, et al: Prevalence of phenotypes of acute 
respiratory distress syndrome in critically ill patients with COVID-19: A 
prospective observational study. Lancet Respir Med 2020 Aug 27. [online 
ahead of print]
 16. Korber B, Fischer WM, Gnanakaran S, et al; Sheffield COVID-19 Genomics 
Group: Tracking changes in SARS-CoV-2 spike: Evidence that D614G 
increases infectivity of the COVID-19 virus. Cell 2020; 182:812–827.e19
DOI: 10.1097/CCE.0000000000000253
